A Delaware federal judge has recently authorized Novartis Pharmaceuticals Corp. to engage with infringement litigation against two companies that have suggested they aim to sell generic versions of Novartis’s highly successful cardiovascular drug, Entresto.
The official litigation proceedings thus allow Novartis to fight the prospective loss of market share, possibly preserving the profitability and exclusivity of their product. Novartis asserts that the two companies’ actions infringe upon their novel and protected intellectual property, thereby prompting this legal battle.
The details of this intricate case continue to unfold and can be followed more comprehensively at Law360.